Peer-reviewed veterinary case report
Pancreatic adenocarcinoma treated with surgical resection, toceranib phosphate and firocoxib in a dog: a case report.
- Journal:
- Veterinary research communications
- Year:
- 2024
- Authors:
- Fuertes-Recuero, Manuel et al.
- Affiliation:
- Department of Physiology · Spain
- Species:
- dog
Plain-English summary
This case involves a 10-year-old intact male beagle diagnosed with a type of pancreatic cancer called ductal pancreatic adenocarcinoma. The diagnosis was confirmed through clinical signs, imaging tests like an abdominal ultrasound and CT scan, and tissue analysis. The dog underwent surgery to remove part of the pancreas, followed by six months of additional treatment with two medications, toceranib phosphate and firocoxib. The dog tolerated the treatment well and lived for 445 days after the diagnosis, which is the longest reported survival time for this type of cancer in dogs. Overall, the treatment was effective in extending the dog's life.
Abstract
Exocrine pancreatic carcinomas are rarely reported in dogs. A ductal pancreatic adenocarcinoma in a 10-year-old intact beagle is described in this report. The diagnosis was made based on clinical signs, imaging (abdominal ultrasound and CT scan) and histopathology. Treatment consisted of partial right lobe pancreatectomy followed by adjuvant therapy with toceranib phosphate (Palladia®) and firocoxib (Previcox®) for six months. The treatment was well tolerated, and the survival time was 445 days. To our knowledge, this is the longest survival reported in the literature for a dog diagnosed with exocrine pancreatic adenocarcinoma. The results described here may contribute to provide a better understanding about this neoplasia and potential treatment options.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/38453822/